MRI联合血清CA125、CA199对Ⅰ期上皮性卵巢癌的诊断价值

详细信息    查看全文 | 推荐本文 |

英文篇名：Diagnostic Value of MRI Combined with Serum CA125 and CA199 for Stage Ⅰ Epithelial Ovarian Cancer 作者：王灵芝 ; 王健 ; 张攀 ; 李静 英文作者：WANG Ling-zhi;WANG Jian;ZHANG Pan;Department of Obstetrics, the First Affiliated Hospital of Henan University of Science and Technology; 关键词：Ⅰ期上皮性卵巢癌 ; MRI ; CA125 ; CA199 英文关键词：Stage Ⅰ epithelial Ovarian Cancer;;MRI;;CA125;;CA199 中文刊名：CTMR 英文刊名：Chinese Journal of CT and MRI 机构：河南科技大学第一附属医院产科;河南科技大学第一附属医院CT室; 出版日期：2019-02-15 出版单位：中国CT和MRI杂志 年：2019 期：v.17;No.112 语种：中文; 页：CTMR201902018 页数：3 CN：02 ISSN：44-1592/R 分类号：61-63

摘要

目的探讨MRI联合糖类抗原125(CA125)及糖类抗原199(CA199)对Ⅰ期上皮性卵巢癌的临床诊断价值。方法选择经病理切片证实的Ⅰ期上皮性卵巢癌患者49例为观察组,42例妇科良性疾病患者为良性组,53例健康体检者作为对照组,对三组被研究者的MRI资料与血清检测中CA125、CA199含量进行比较分析。结果对照组、良性组及观察组患者体内CA125血清因子含量比较,差异具有统计学意义(F=33.630,P<0.05);三组中CA199血清因子含量比较,差异具有统计学意义(F=28.017,P<0.05)。与单独指标检测阳性率相比,联合CA125与CA199阳性检出率显著提高(P<0.05),联合MRI与血清因子CA125、CA199含量变化阳性检出率显著提高(P<0.05)。与单独指标检测灵敏度相比,联合CA125及CA199、联合MRI与血清因子CA125、CA199,灵敏度均升高。结论MRI与血清因子CA125、CA199联合检测Ⅰ期上皮性卵巢癌患者的阳性率提高,有利于提高Ⅰ期上皮性卵巢癌患者的临床诊出率。
        Objective To explore the clinical diagnostic value of MRI combined with carbohydrate antigen 125(CA125) and carbohydrate antigen 199(CA199) in the diagnosis of stage I epithelial ovarian cancer. Methods A total of 49 cases of patients with stage I epithelial ovarian cancer confirmed by pathological section were selected as observation group, and 42 cases were benign gynecological diseases and were selected as benign group, and 53 healthy examiners were included into control group. MRI data and serum contents of CA125 and CA199 were compared and analyzed in the three groups. ResultsThere was a statistically significant difference in the serum CA125 level among control group, benign group and observation group(F=33.630, P<0.05). There was a statistically significant difference in the serum level of CA199 in the three groups(F=28.017, P <0.05). Compared with the positive detection rate of individual indicators, the positive detection rate of combined CA125 and CA199 was significantly increased(P<0.05), and the positive detection rate of combined MRI and serum factors CA125 and CA199 was significantly increased(P<0.05). Compared with the sensitivity of individual indicators, the sensitivities of combined CA125 and CA199, and combined MRI and serum factors CA125 and CA199 were increased. Conclusion The positive rate of MRI combined with serum factors CA125 and CA199 is increased in the detection of stage I epithelial ovarian cancer, which is beneficial to improve the clinical diagnosis rate of patients with stage I epithelial ovarian cancer.

引文

[1]Gubbels J A,Claussen N,Kapur A K,et al.The detection, treatment, and biology of epithelial ovarian cancer[J].Journal of Ovarian Research,2010,3(8):1-11.
    [2] Berek J S,Crum C,Friedlander M.Cancer of the ovary, fallopian tube,and peritoneum-International Journal of Gynecology and Obstetrics[J].International Journal of Gynaecology&Obstetrics the Official Organ of the International Federation of Gynaecology&Obstetrics,2012,119suppl 2(1):S118-129.
    [3]崔恒.卵巢癌的早期诊断[J].中国妇产科临床杂志,2010, 11(6):403-405.
    [4]赵肖波,陶洁,孙静,等.血清CA125用于预测上皮性卵巢癌、输卵管癌及腹膜癌化疗反应性的研究[J].现代妇产科进展,2012,21(8):596-599.
    [5]李彦伟,俞志杰.8例卵巢透明细胞癌CT影像学表现分析[J].中国CT和MRI杂志,2017,15(8):109-111.
    [6]任继鹏,孟楠,周凤梅,等.多模型体素不相干运动联合血清CA125对卵巢肿瘤的诊断价值[J].中国CT和MRI杂志,2018,16(3):79-82.
    [7]张海萍,李威威,吴敏.优质护理对卵巢癌患者焦虑及抑郁情绪的影响[J].河北医药,2016(3):470-472.
    [8]郎景和.妇科恶性肿瘤筛查[J].中国实用妇科与产科杂志,20 16,32(5):385-389.
    [9] Jacobs I J,Menon U,Ryan A,et al.Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening(UKCTOCS):a randomised controlled trial[J].Lancet,2016,387(10022):945-956.
    [10]Buamah P K,Rake M O,Drake S R,et al.Serum CA 12-5 concentrations and CA 12-5/CEA ratios in patients with epithelial ovarian cancer[J].Journal of Surgical Oncology,2010,44(2):97-99.
    [11]Anastasi E,Marchei G G,Viggiani V,et al.HE4:a new potential early biomarker for the recurrence of ovarian cancer[J].Tumor Biology,20 1 0, 31(2):113-119.
    [12]Jacobs I J,Menon U.Progress and challenges in screening for early detection of ovarian cancer[J].Molecular&Cellular Proteomics,2004,3(4):355-366.
    [13]Kolwijck E,Bulten T J, Massuger L F A G.Preoperative CA-125 Levels in123 Patients With Borderline Ovarian Tumors A Retrospective Analysis and Review of the Literature[J].International Journal of Gynecological Cancer,2010, 19(8):1335-1338.
    [14]Moore R G,Maclaughlan S,Jr B R.Current state of biomarker development for clinical application in epithelial ovarian cancer[J].Gynecologic Oncology,2010,116(2):240-245.
    [15]李波,黄劲柏,熊霞.与左肝管相通肝内胆管囊腺癌1例[J].实用医学杂志,2016,32(9):1550-1551.